%0 Journal Article %T Transcatheter mitral valve replacement for degenerated mitral bioprostheses: a systematic review %A Eleid, Mackram F. %A Rihal, Charanjit S. %A Guerrero, Mayra E. %J Annals of Cardiothoracic Surgery %D 2021 %B 2021 %9 %! Transcatheter mitral valve replacement for degenerated mitral bioprostheses: a systematic review %K %X Background: Treatment of degenerated mitral bioprostheses with transcatheter mitral valve-in-valve (MVIV) implantation is increasingly used. The goal of this review was to evaluate the one-year outcomes of this therapy using the most recent evidence. Methods: A MEDLINE, Cochrane database and SCOPUS search was performed of published observational studies involving patients undergoing transcatheter MVIV for degenerated bioprosthesis to determine procedural success, thirty-day and one-year survival. Results: A total of 2,684 patients undergoing transcatheter MVIV were identified from five studies with mean age of 73–75 years, 57–63% female and Society for Thoracic Surgery (STS) risk score ranging from 9–13%. Procedural technical success ranged from 94–98%, with 1–3% rates of periprocedural death, 0–2% stroke and 1–5% risk of left ventricular outflow tract (LVOT) obstruction. Thirty-day post-procedure mean mitral prosthetic gradient ranged from 6–7 mmHg and residual mitral regurgitation was mild or less in 96–100% of patients. Thirty-day survival and one-year survival ranged from 93–97% and 83–89% respectively. Conclusions: Transcatheter MVIV is an effective treatment for structural degeneration of biologic mitral valve replacement with low complication rates and favorable one-year outcomes. Accordingly, MVIV should be considered as a reasonable alternative to re-do surgical mitral valve replacement in high risk patients with comorbidities. Further study of long-term outcomes of this treatment is needed. %U https://www.annalscts.com/article/view/16845 %V 10 %N 5 %P 558-563 %@ 2304-1021